Diatide shares priced at $8.5 in initial public offering (IPO)
This article was originally published in Clinica
Diatide (US) is to offer 2.2 million shares at $8.5 each in an initial public offering, somewhat lower than the 2.5 million shares at $10-$12 quoted in the prospectus. The New Hampshire-based company, formally known as Diatech, develops radiopharmaceuticals for use in nuclear medicine imaging procedures. The company has 42 employees, 27 of whom are engaged in R&D.